Imaging and Cerebrospinal Fluid Biomarkers in the Search for Alzheimer's Disease Mechanisms

Background: The pathophysiological process of Alzheimer's disease (AD) begins many years before the emergence of clinical symptoms (preclinical AD). A hypothetical biomarker progression in the pathogenesis of AD has been suggested, beginning with the deposition of amyloid-beta (A beta) and followed by increases in neurofibrillary tangles, synaptic loss, hippocampal atrophy, and lastly, cognitive impairment. Objective: We explored the effect of several risk factors for AD on the pattern of AD biomarker expression in normal subjects. Methods: AD biomarker evidence was examined at baseline in 96 cognitively normal elderly subjects with none or at least one of the following: ApoE4+ allele, a maternal history of AD (mFHx), sleep-disordered breathing (SDB), and longitudinal evidence of decline to mild cognitive impairment or AD (decliners) at follow-up. Results: Decliners and ApoE4+ subjects presented with expected reduced cerebrospinal fluid A beta 42, elevated P-tau and T-tau. In addition, decliners had fluorodeoxyglucose positron emission tomography hypometabolism in the medial temporal lobe. Individuals with mFHx demonstrated no A beta 42 effect, but had elevations in P-tau and T-tau. SDB was found to be associated with elevated A beta 42, P-tau and T-tau, as well as with reduced medial temporal lobe glucose metabolic rates. Conclusion: Our results indicate a heterogeneous biomarker expression, suggesting diversity of AD pathways in at-risk presymptomatic subjects. (C) 2013 S. Karger AG, Basel